SCHEMBL5635463

SCHEMBL5635463

CNC(=O)c1ncccc1Oc1ccc(NC(=O)CC(=O)Nc2ccc(Cl)c(C(F)(F)F)c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 9/20 0.58
BRAF P15056 9/20 0.58
RET P07949 3/20 0.58
KDR P35968 3/20 0.58
CDK8 P49336 2/20 0.58
CSF1R P07333 2/20 0.58
PDGFRB P09619 2/20 0.58
KIT P10721 2/20 0.58
PDGFRA P16234 2/20 0.58
DDR1 Q08345 2/20 0.58
MEN1 O00255 1/20 0.58
PLK4 O00444 1/20 0.58
CIT O14578 1/20 0.58
AURKA O14965 1/20 0.58
MUSK O15146 1/20 0.58
EPHB6 O15197 1/20 0.58
MAPK13 O15264 1/20 0.58
MLNR O43193 1/20 0.58
MAP3K7 O43318 1/20 0.58
RIPK2 O43353 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29664907 0.93 RAF1 (0.68) RAF1BRAFRETKDRCDK8
SCHEMBL1412957 0.93 RAF1 (0.68) RAF1BRAFRETKDRCDK8
SCHEMBL30448225 0.88 BRAF (0.54) RAF1BRAFRETKDRCDK8
SCHEMBL2559430 0.84 BRAF (0.72) RAF1BRAFRETKDRCDK8
SCHEMBL28415556 0.82 BRAF (0.63) RAF1BRAFRETKDRCDK8
SCHEMBL31255796 0.82 BRAF (0.58) RAF1BRAFRETKDRCDK8
SCHEMBL5635314 0.81 RAF1 (0.86) RAF1BRAFRETKDRCDK8
SCHEMBL6051249 0.81 BRAF (0.69) RAF1BRAFRETKDRCDK8
SCHEMBL28896139 0.79 BRAF (0.49) RAF1BRAFRETKDRCDK8
SCHEMBL14422917 0.78 RET (0.69) RAF1BRAFRETKDRCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641759-B1 MALONAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-12 EP disclosed
US-20070213374-A1 Malonamide Derivatives MERCK PATENT GMBH (DE) 2007-09-13 US disclosed
EP-1641759-A2 MALONAMIDE DERIVATIVES MERCK PATENT GmbH (DE) 2006-04-05 EP disclosed
WO-2005005389-A2 MALONAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213374-A1 Malonamide Derivatives RAF1, BRAF, ARAF RAF1 1/4885BRAF 2/4885RET 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.